2026 Global: 23-Valent Pneumococcal Vaccine Market -Competitive Review (2032) report
Description
The 2026 Global: 23-Valent Pneumococcal Vaccine Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for 23-valent pneumococcal vaccine market by geography and historical trend. The scope of the report extends to sizing of the 23-valent pneumococcal vaccine market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Pfizer, GlaxoSmithKline (GSK), Merck & Co., Sanofi Pasteur, CSL, Serum Institute of India, Walvax Biotechnology, Vaxcyte, Beijing Minhai (Shenzhen Kangtai subsidiary), and Bharat Biotech are among the ten major companies active in the 23‑valent pneumococcal vaccine (PPSV23) market, each contributing through established products, regional supply, or emerging PPSV23 offerings. Pfizer’s broad vaccine portfolio and dominant Prevnar conjugate franchise sustain its leadership in pneumococcal prevention while its market strength also shapes demand dynamics for PPSV23 in adult immunization programs. GSK leverages long-standing vaccine expertise and global distribution networks, supporting both conjugate and polysaccharide segments and securing tender wins in diverse markets where PPSV23 remains a key adult vaccine option. Merck combines a diversified vaccine pipeline with recent adult conjugate approvals, positioning it to influence PPSV23 usage through competitive pricing and programmatic decisions that affect polysaccharide uptake. Sanofi Pasteur’s investment in next‑generation pneumococcal candidates and global manufacturing capacity underpins its role in adult immunization strategies where PPSV23 continues to be part of national schedules and catch‑up campaigns. CSL contributes through specialty and adult vaccine channels, supporting regional immunization needs and procurement frameworks that include 23‑valent polysaccharide products in some markets. The Serum Institute of India supplies high‑volume, lower‑cost vaccine doses for low‑ and middle‑income countries, influencing PPSV23 accessibility through tender participation and partnerships that expand adult vaccine coverage in resource‑constrained settings. Walvax Biotechnology has developed and distributed a preservative‑free PPSV23 with substantial deployment across several countries, presenting a notable new supplier that increases global PPSV23 availability and competitive pricing in Asia and selected emerging markets. Vaxcyte, while best known for advancing high‑valency conjugate candidates, affects the PPSV23 market indirectly by driving interest in broader‑coverage alternatives and by entering adult vaccine discussions that may reshape polysaccharide demand curves as novel conjugates advance through trials. Beijing Minhai (a Shenzhen Kangtai subsidiary) participates in domestic Chinese supply chains and regional exports, offering PPSV23 and related pneumococcal products that bolster local immunization programs and tender outcomes in Asia. Bharat Biotech, with experience in large‑scale vaccine manufacturing and national immunization partnerships, supports regional adult vaccination initiatives and can serve as a strategic PPSV23 supplier in India and neighboring countries where polysaccharide vaccines remain integral to adult immunization schedules.
Taken together, these ten companies represent a mix of multinational innovators, regional manufacturers, and emerging suppliers whose combined activities determine PPSV23 production capacity, price competition, and geographic access; Pfizer, GSK, and Merck exert outsized influence through market share and product portfolios, while suppliers such as Serum Institute, Walvax, Beijing Minhai, and Bharat Biotech expand supply to low‑ and middle‑income markets and Vaxcyte’s high‑valency efforts, plus Sanofi and CSL’s development programs, are shifting long‑term demand away from polysaccharide reliance toward broader conjugate strategies in many jurisdictions.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for 23-valent pneumococcal vaccine market by geography and historical trend. The scope of the report extends to sizing of the 23-valent pneumococcal vaccine market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Pfizer, GlaxoSmithKline (GSK), Merck & Co., Sanofi Pasteur, CSL, Serum Institute of India, Walvax Biotechnology, Vaxcyte, Beijing Minhai (Shenzhen Kangtai subsidiary), and Bharat Biotech are among the ten major companies active in the 23‑valent pneumococcal vaccine (PPSV23) market, each contributing through established products, regional supply, or emerging PPSV23 offerings. Pfizer’s broad vaccine portfolio and dominant Prevnar conjugate franchise sustain its leadership in pneumococcal prevention while its market strength also shapes demand dynamics for PPSV23 in adult immunization programs. GSK leverages long-standing vaccine expertise and global distribution networks, supporting both conjugate and polysaccharide segments and securing tender wins in diverse markets where PPSV23 remains a key adult vaccine option. Merck combines a diversified vaccine pipeline with recent adult conjugate approvals, positioning it to influence PPSV23 usage through competitive pricing and programmatic decisions that affect polysaccharide uptake. Sanofi Pasteur’s investment in next‑generation pneumococcal candidates and global manufacturing capacity underpins its role in adult immunization strategies where PPSV23 continues to be part of national schedules and catch‑up campaigns. CSL contributes through specialty and adult vaccine channels, supporting regional immunization needs and procurement frameworks that include 23‑valent polysaccharide products in some markets. The Serum Institute of India supplies high‑volume, lower‑cost vaccine doses for low‑ and middle‑income countries, influencing PPSV23 accessibility through tender participation and partnerships that expand adult vaccine coverage in resource‑constrained settings. Walvax Biotechnology has developed and distributed a preservative‑free PPSV23 with substantial deployment across several countries, presenting a notable new supplier that increases global PPSV23 availability and competitive pricing in Asia and selected emerging markets. Vaxcyte, while best known for advancing high‑valency conjugate candidates, affects the PPSV23 market indirectly by driving interest in broader‑coverage alternatives and by entering adult vaccine discussions that may reshape polysaccharide demand curves as novel conjugates advance through trials. Beijing Minhai (a Shenzhen Kangtai subsidiary) participates in domestic Chinese supply chains and regional exports, offering PPSV23 and related pneumococcal products that bolster local immunization programs and tender outcomes in Asia. Bharat Biotech, with experience in large‑scale vaccine manufacturing and national immunization partnerships, supports regional adult vaccination initiatives and can serve as a strategic PPSV23 supplier in India and neighboring countries where polysaccharide vaccines remain integral to adult immunization schedules.
Taken together, these ten companies represent a mix of multinational innovators, regional manufacturers, and emerging suppliers whose combined activities determine PPSV23 production capacity, price competition, and geographic access; Pfizer, GSK, and Merck exert outsized influence through market share and product portfolios, while suppliers such as Serum Institute, Walvax, Beijing Minhai, and Bharat Biotech expand supply to low‑ and middle‑income markets and Vaxcyte’s high‑valency efforts, plus Sanofi and CSL’s development programs, are shifting long‑term demand away from polysaccharide reliance toward broader conjugate strategies in many jurisdictions.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.